Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Tamar Tadmor; Ohad Benjamini; Andrei Braester; Galia Rahav; Lior Rokach

doi:10.1038/s41375-021-01380-5

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Tamar Tadmor, Ohad Benjamini, Andrei Braester, Galia Rahav, Lior Rokach

Research output: Contribution to journal › Letter › peer-review

21 Scopus citations

Original language	English
Pages (from-to)	2727-2730
Number of pages	4
Journal	Leukemia
Volume	35
Issue number	9
DOIs	https://doi.org/10.1038/s41375-021-01380-5
State	Published - Sep 2021
Externally published	Yes

Funding

Funders	Funder number
Janssen Pharmaceuticals	EV00261620

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-021-01380-5

Cite this

@article{d892f9a6b5ca4d37a2aa23a08b8629b1,

title = "Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia",

author = "Tamar Tadmor and Ohad Benjamini and Andrei Braester and Galia Rahav and Lior Rokach",

year = "2021",

month = sep,

doi = "10.1038/s41375-021-01380-5",

language = "אנגלית",

volume = "35",

pages = "2727--2730",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

AU - Tadmor, Tamar

AU - Benjamini, Ohad

AU - Braester, Andrei

AU - Rahav, Galia

AU - Rokach, Lior

PY - 2021/9

Y1 - 2021/9

UR - https://www.scopus.com/pages/publications/85112139438

U2 - 10.1038/s41375-021-01380-5

DO - 10.1038/s41375-021-01380-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 34376803

AN - SCOPUS:85112139438

SN - 0887-6924

VL - 35

SP - 2727

EP - 2730

JO - Leukemia

JF - Leukemia

IS - 9

ER -

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Funding

UN SDGs

Access to Document

Other files and links

Cite this